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ABSTRACT
Preclinical positron emission tomography (PET) imaging revealed a mismatch 
between in vivo epidermal growth factor receptor (EGFR) expression and EGFR 
antibody tracer tumor uptake. Shed EGFR ectodomain (sEGFR), which is present 
in cancer patient sera, can potentially bind tracer and therefore influence tracer 
kinetics. To optimize EGFR-PET, we examined the influence of sEGFR levels on tracer 
kinetics and tumor uptake of EGFR monoclonal antibody 89Zr-imgatuzumab in varying 
xenograft models. Human cancer cell lines A431 (EGFR overexpressing, epidermoid), 
A549 and H441 (both EGFR medium expressing, non-small cell lung cancer) were 
xenografted in mice. Xenografted mice received 10, 25 or 160 μg 89Zr-imgatuzumab, 
co-injected with equal doses 111In-IgG control. MicroPET scans were made 24, 72 and 
144 h post injection, followed by biodistribution analysis. sEGFR levels in liver and 
plasma samples were determined by ELISA. 89Zr-imgatuzumab uptake in A431 tumors 
was highest (29.8 ± 5.4 %ID/g) in the 160 μg dose group. Contrary, highest uptake 
in A549 and H441 tumors was found at the lowest (10 μg) 89Zr-imgatuzumab dose. 
High 89Zr-imgatuzumab liver accumulation was found in A431 xenografted mice, which 
decreased with antibody dose increments. 89Zr-imgatuzumab liver uptake in A549 and 
H441 xenografted mice was low at all doses. sEGFR levels in liver and plasma of A431 
bearing mice were up to 1000-fold higher than levels found in A549, H441 and non-
tumor xenografted mice. 89Zr-imgatuzumab effectively visualizes EGFR-expressing 
tumors. High sEGFR levels can redirect 89Zr-imgatuzumab to the liver, in which case 
tumor visualization can be improved by increasing tracer antibody dose. 
INTRODUCTION 
Overexpression and mutations of epidermal growth 
factor receptor (EGFR) are associated with tumor cell 
growth, differentiation, proliferation, apoptosis and cellular 
invasiveness [1]. Clinical treatment options for KRAS wild-
type EGFR in head and neck squamous cell carcinoma 
(HNSCC) and metastatic colorectal cancer (mCRC), 
encompass monoclonal antibodies (mAbs) cetuximab and 
panitumumab. Mutant EGFR expressing tumors, including 
non-small cell lung cancer (NSCLC), are treated with the 
tyrosine kinase inhibitors erlotinib and gefitinib [2–4]. 
EGFR-targeted therapy might be improved by 
optimizing antibody-dependent cell-mediated cytoxicity 
(ADCC) responses. Imgatuzumab (GA201) is a novel 
humanized anti-EGFR IgG1 isotype mAb, glycoengineered 
for enhanced ADCC, as well as inhibiting ligand-
dependent signaling of EGFR. Imgatuzumab recognizes 
human EGFR and is not cross-reactive with murine EGFR 
[5]. It showed superior in vivo efficacy compared to 
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cetuximab and non-glycoengineered imgatuzumab in both 
KRAS-mutant and KRAS-wild type tumor models. In phase 
1 studies imgatuzumab demonstrated promising efficacy in 
heavily pretreated patients with advanced EGFR-positive 
solid tumors and KRAS-mutant EGFR-positive advanced 
colorectal cancer [6, 7].
Whole body determination of EGFR expression 
in lesions using molecular imaging could support 
decision making during clinical development and clinical 
practice. Antibody biodistribution can be visualized by 
labeling mAbs with the PET isotope Zirconium-89 (89Zr, 
t½ = 78.4 h). We previously developed and successfully 
tested 89Zr-labeled antibody-based tracers targeting 
human epidermal growth factor receptor 2 (HER2), 
vascular endothelial growth factor (VEGF) and HER3 
in the preclinical and clinical setting [8–12]. 89Zr-labeled 
antibodies have also been developed for preclinical EGFR 
imaging [13–15]. Furthermore, clinical EGFR imaging 
has been performed with 89Zr-cetuximab in advanced 
colorectal cancer patient [16,17]. Additional clinical 
studies are currently ongoing for both 89Zr-cetuximab 
and 89Zr-panitumumab (ClinicalTrial.gov identifiers 
NCT01691391, NCT02117466 and NCT02192541). 
Unfortunately, preclinical EGFR antibody-based 
imaging studies revealed a mismatch between in vivo 
EGFR protein expression and tumor tracer uptake 
[13, 17]. Many factors have been suggested for this 
mismatch, including perfusion rates, vascularity, vascular 
permeability, interstitial pressure and mAb plasma half-
life [17]. Circulating HER2 extracellular domain (ECD) 
and trastuzumab are known to form complexes, which 
are swiftly cleared by the liver [18]. Underscoring the 
possibility of shed ECD to significantly influence kinetics 
of antibodies, shed HER2 serum levels over 500 ng/mL 
extensively influenced trastuzumab kinetics in patients at 
weekly doses of 100 mg trastuzumab [19]. For EGFR and 
EGFR-targeting mAbs this relation is less clear. However, 
some studies show extensive levels of circulating soluble 
EGFR extracellular domain (sEGFR) in patients and 
healthy volunteers [20]. sEGFR might therefore also 
influence kinetics and tumor uptake of tracer doses used 
for 89Zr-labeled EGFR targeting antibodies. 
In order to optimize EGFR imaging and visualize 
EGFR expression in vivo we developed the EGFR PET 
tracer 89Zr-imgatuzumab and examined the influence of 
sEGFR on 89Zr-imgatuzumab tracer kinetics and tumor 
uptake in multiple xenograft models using microPET 
imaging.
RESULTS
89Zr-imgatuzumab tracer development and 
quality control
Df-imgatuzumab conjugate bound up to 500 MBq 
89Zr/mg Df-imgatuzumab at a radiochemical purity (RCP) 
≥ 95% after radiolabeling, without further purification 
(Supplementary Figure S1A). SE-HPLC revealed 
absence of aggregates and fragments in Df-imgatuzumab 
conjugates. The immunoreactive fraction of Df-
imgatuzumab conjugate was assessed by competition assay 
at 68.9 ± 6.3% compared to unmodified imgatuzumab 
(Supplementary Figure S1B). 89Zr-imgatuzumab was stable 
in vitro, the maximum observed decrease in RCP was from 
99.4 ± 0.1% to 93.4 ± 0.8% in 0.5 M HEPES buffer pH 
7.2 after 14 days at 37°C (Supplementary Figure S1C). 
All batches of 89Zr-imgatuzumab used as tracer had a RCP 
≥ 95% by TCA precipitation, while 111In-IgG batches had 
a RCP ≥ 90% by ITLC.
MicroPET imaging and biodistribution in 
different tumor models
MicroPET analysis showed preferential tumor 
uptake of 89Zr-imgatuzumab in A431, A549 and H441 
xenografts models (Figure 1A). For A549 and H441, the 
highest 89Zr-imgatuzumab tumor uptake was observed for 
the 10 μg dose 6 days pi (Figure 1B), while higher doses 
lowered tumor uptake. An opposite pattern was observed 
in A431 tumors, where 89Zr-imgatuzumab tumor uptake 
increased with increasing tracer dose (Figure 1B). Blood 
levels of 89Zr-imgatuzumab were highest for the 160 μg 
tracer dose at day 1 pi for all tested models and decreased 
gradually over time (Figure 1B). 89Zr-imgatuzumab blood 
levels were significantly lower in A431 tumor bearing 
mice compared to both A549 and H441 at 10 μg and 
25 μg (P < 0.001) and at 160 μg (A549: P < 0.01, H441: 
P < 0.05). High liver accumulation was observed in A431 
compared to both A549 and H441 tumor bearing mice at 
10 μg (P < 0.001) and at 25 μg (P < 0.01), but not in the 
160 μg tracer dose group (Figure 1A, 1B).
Biodistribution studies showed that 89Zr-
imgatuzumab uptake in A431 tumors was not different 
from 111In-IgG uptake in the 10 μg dose group (8.4 ± 
1.0 vs. 7.7 ± 0.7%ID/g, P = 0.50), but after increasing 
the dose to 25, 100 and 160 μg, significant tumor 
uptake was observed. Highest A431 tumor uptake was 
observed at 160 μg tracer dose, with 29.8 ± 5.4 %ID/g 
for 89Zr-imgatuzumab, compared to 9.8 ± 1.1 %ID/g 
for 111In-IgG uptake (P < 0.05) (Figure 2). Tumor-to-
blood ratios of all tracer doses in A431 tumor bearing 
mice were consistently higher for 89Zr-imgatuzumab 
compared to 111In-IgG, revealing absolute tracer uptake 
in A431 tumors was limited by blood pool availability 
of 89Zr-imgatuzumab (Figure 3). Tracer uptake in A549 
in tumors was the highest for the 10 μg dose group at 
12.2 ± 2.1%ID/g for 89Zr-imgatuzumab vs. 7.2 ± 1.5 
%ID/g for 111In-IgG (P = 0.13), while tumor-to-blood 
values for 10 and 25 μg were significantly higher for 
89Zr-imgatuzumab compared to 111In-IgG. The highest 
specific tumor uptake in H441 tumors was observed with 
10 μg 89Zr-imgatuzumab (28.0 ± 1.6%ID/g) compared to 
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111In-IgG (9.8 ± 1.6%ID/g, P < 0.01), whereas at 160 μg 
89Zr-imgatuzumab tumor uptake (14.2 ± 1.7%ID/g) was 
similar to 111In-IgG (19.2 ± 5.0%ID/g, Figure 2). Both 
A549 and H441 tumors showed target saturation at the 
160 μg dose (Figures 2, 3). Tumor-to-blood ratios for 
both A549 and H441 showed a similar pattern to absolute 
uptake data, denoting uptake of 89Zr-imgatuzumab in 
these tumors was not limited by blood pool availability 
(Figure 3). 
High liver uptake of 20.9 ± 1.3%ID/g was observed 
in mice bearing A431 tumors at 10 μg 89Zr-imgatuzumab, 
this was higher than for A549 (6.5 ± 0.5%ID/g, 
P < 0.0001) and H441 (8.5 ± 1.0%ID/g, P < 0.001) 
bearing mice at equal dose. Liver uptake in A431 bearing 
mice could be blocked by increasing the tracer antibody 
dose, as can be seen by the decreasing differences between 
89Zr-imgatuzumab and 111In-IgG liver uptake (Figure 2). 
Specific spleen uptake of 89Zr-imgatuzumab was observed 
in all tumor models, which was saturable at higher 
doses, as shown by decreasing differences between 
89Zr-imgatuzumab and 111In-IgG spleen uptake at higher 
tracer doses (Figure 2). 
EGFR expression analysis and 
immunohistochemistry
EGFR cell surface expressions in vitro by flow 
cytometric analysis (Figure 4B) and ex vivo by ELISA in 
tumor lysates (Figure 4C) were concordant. Expression 
level of EGFR per gram protein based upon ELISA was 
highest in A431, followed in declining order by A549 
and H441 xenografts. All xenograft tumors expressed 
EGFR as determined by IHC (Figure 4A). Highest EGFR 
H-score was found in A431, followed by H441 and the 
least amount of staining was found in A549 xenografts 
(Figure 4A and  4D). A549 tumor cell density was 
markedly lower compared with A431 and H441 tumors 
(Figure 4A). Microvascular density was found to be 
similar in all three xenograft models (Figure 4E).
sEGFR analysis of plasma, liver and cell lysates
ELISA showed high sEGFR levels (831 ± 71 ng/mL) 
in plasma of A431 tumor bearing, which were three 
magnitudes higher than observed in A549, H441 and 
Figure 1: (A) Representative maximal intensity projections of microPET scans 144 h after tracer injection for 10, 25 and 160 μg 
doses of 89Zr-imgatuzumab in A431, A549 and H441 xenograft bearing mice. Livers are marked with L, while xenografts are 
marked with an arrow. (B) MicroPET quantification for tumor, liver and blood pool at 24, 72 and 144 h after tracer injection for 10, 25 and 
160 μg tracer dose in A431, A549 and H441 xenograft bearing mice. Data are expressed as SUVmean ± SEM. 
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non-tumor bearing control mice (P < 0.01). A549 and H441 
sEGFR plasma levels did not deviate from background 
measurement in plasma of non-tumor bearing control 
mice (Figure 5A). sEGFR levels were also elevated at 
790 ± 109 ng/g protein sEGFR in liver lysates of A431 
xenograft bearing mice (P < 0.01), but not in A549 and 
H441 when compared to non-tumor bearing control mice 
(Figure 5B). To confirm the shedding potential of A431 
in vitro, confluent cell cultures serum-free supernates 
were tested for sEGFR. sEGFR levels in A431 supernates 
(999 ± 21 ng/ml) were approximately 1000-fold higher 
(P < 0.001) compared to A549 and H441 (0.06 ± 0.004, 
respectively 0.87 ± 0.03 ng/ml) (Figure 5C). sEGFR 
in supernates from serum-containing media cultures 
showed a similar pattern and equal magnitude, indicating 
inhibition of proteolytical cleavage by serum did not 
influence the amount of sEGFR shedding in these cell 
lines (Figure 5D). Serum-free and serum-containing media 
controls were negative for sEGFR.
DISCUSSION 
This is the first paper showing tumor uptake of an 
EGFR-targeted antibody tracer can be affected by EGFR 
shedding. High levels of sEGFR acted as antigen sink, 
redirecting 89Zr-imgatuzumab to the liver, which reduced 
tumor uptake at lower tracer doses in A431 xenografts. 
Contrarily, in A549 and H441 xenografts models, lacking 
detectable EGFR shedding, low liver uptake was observed 
and tumor uptake could be saturated by 89Zr-imgatuzumab 
dose increments.
A431 xenografts showed the highest tumor uptake 
at the highest tracer dose used. Specific liver uptake of 
89Zr-imgatuzumab was observed, which decreased with 
dose increments in A431 bearing mice. In previous 
preclinical EGFR antibody-based imaging studies 
revealing mismatch between xenograft EGFR expression 
and tracer uptake, a large role was postulated for vascularity 
and vascular permeability for tracer delivery in the tumor 
Figure 2: Ex vivo uptake data for tumor, liver, spleen and blood, presented as % ID/g 89Zr-imgatuzumab and 111In-IgG 
non-specific control, for 10, 25 and 160 μg doses in A431, A549 and H441 xenograft bearing mice.
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[13, 17]. Our results show that in addition to vascular 
differences between xenografts, circulating sEGFR can 
act as antigen sink and decrease tumor tracer uptake. 
Complexation of 89Zr-imgatuzumab and sEGFR, followed 
by liver sequestration as shown by ELISA, resulted in high 
89Zr-imgatuzumab liver uptake, low blood pool availability 
and consequently relatively low uptake in A431 xenograft 
tumors at low tracer protein doses.
In contrast, in A549 and H441 xenografts low 
89Zr-imgatuzumab liver uptake and sEGFR plasma levels 
were observed. In these models 89Zr-imgatuzumab tumor 
uptake was dose dependent, with highest uptake observed 
for low tracer protein doses, comparable to earlier findings 
for various antibody-based tracers targeting HER family 
members [8, 10, 15]. Higher 89Zr-imgatuzumab tumor uptake 
was found in H441 compared to A549 xenografts in our 
Figure 3: Tumor-to-blood ratios of 89Zr-imgatuzumab and 111In-IgG for indicated doses in A431, A549 and H441 
xenograft bearing mice.
Figure 4: (A) Ex vivo tissue analysis. Mean vessel density (MVD), EGFR and hematoxylin and eosin immunohistochemical staining 
of A431, A549 and H441 tumors. (B) In vitro flow cytometric analysis of EGFR membrane expression in A431, A549 and H441 cells. 
(C) Ex vivo human EGFR extracellular domain levels in A431, A549 and H441 tumor tissue lysates. (D) EGFR histo-score (H-score) for 
A431, A549 and H441 tumors. (E) Mean vessel density score for A431, A549 and H441 tumors. 
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study, despite lower in vitro and ex vivo EGFR expression 
based upon ELISA. No difference in microvascular density 
was found between all models. Therefore, differences 
in 89Zr-imgatuzumab uptake in A549 and H441 are most 
likely explained by the lower EGFR expression based upon 
EGFR histoscore, combined with lower tumor cell density 
on H&E in A549. Furthermore, vascular permeability in 
the H441 is higher, as shown by the high accumulation 
of 111In-IgG control at higher doses, which was also 
seen in an earlier study [10]. Specific spleen uptake of 
89Zr-imgatuzumab was observed in all tumor models, which 
decreased with 89Zr-imgatuzumab dose increments. Spleen 
targeting of 89Zr-imgatuzumab can be explained by its 
affinity, through glycoengineering, for the murine analog 
of the FcyRIIIA receptor, FcγRIV, on macrophages and 
monocytes [5] and resembles our experience with similarly 
glycoengineered HER3 mAb 89Zr-RG7116 [10].
Several isoforms of circulating sEGFR have been 
found in ovarian, metastatic breast and non-small cell 
lung cancer patients and healthy volunteers [21–24]. All 
sEGFR isoforms contain subdomain III of the EGFR 
extracellular domain, to which EGFR mAbs imgatuzumab, 
cetuximab and panitumumab bind [25, 26], but lack the 
transmembrane and cytoplasmic domains of the EGFR 
receptor [21, 22]. While cetuximab is known to inhibit 
sEGFR shedding in vitro (27), it is currently unknown 
whether imgatuzumab has potential to inhibit sEGFR 
shedding. sEGFR is commonly shed by proteolytic 
cleavage from human carcinoma cells expressing over 
7 × 105 EGFR receptors [27]. Of the present cell panel, 
only A431 is known to shed a ~105 kDa sEGFR isoform, 
due to an aberrant transcript, as well as a 110 kDa sEGFR 
isoform [29–31]. Because of its aberrant sEGFR shedding 
potential, the A431 cell line was used to reliable induce 
human sEGFR shedding in a murine system and served 
as a model for the interaction between the endogenous 
sEGFR isoforms and EGFR monoclonal antibody tracers. 
Besides proteolytic cleavage, alternate splicing events 
in normal tissues result in mRNA transcripts encoding 
for 60-kDa, 80-kDa and 110-kDa sEGFR isoforms, that 
are the major source of sEGFR in patients and healthy 
volunteers [22].
sEGFR levels in A431 tumor-bearing mice were 
837 ± 71 ng/mL plasma, corresponding to ~2.5 sEGFR 
for each 89Zr-imgatuzumab molecule in circulation for the 
10 μg tracer dose, reflecting a high degree of competition 
Figure 5: (A) Human EGFR extracellular domain concentration in plasma of A431, A549 and H441 xenograft bearing and 
non-tumor bearing control mice. (B) Human EGFR extracellular domain level in liver tissue lysates of A431, A549 and H441 xenograft 
bearing and non-tumor bearing control mice. (C) Human EGFR extracellular domain concentration in serum-free supernates of confluent 
cell cultures of A431, A549 and H441 cells. (D) Human EGFR extracellular domain concentration in serum-containing supernates of 
confluent cell cultures of A431, A549 and H441 cells, only statistical significances against A431 are shown for clarity.
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of sEGFR with tumor-bound EGFR. Increasing the 
89Zr-imgatuzumab dose to 160 μg, mitigated sEGFR 
competition for tumor bound EGFR, resulting in higher 
tumor uptake. A limited number of preclinical imaging 
studies have included shed or circulating antigen 
measurements. c-MET tracer 89Zr-onartuzumab kinetics 
were not influenced by 14.1 ± 5.2 ng/mL per gram 
tumor shed c-MET in MKN-45 xenografts at high tracer 
doses of 64 to 128 μg [31]. However, similar to our 
results, high CA19.9 mAb 89Zr-5B1 liver uptake and 
decreasing tumor uptake over time was observed for in 
Colo205-Luc xenografts secreting large amounts CA19.9 
(2500 ± 1033 U/mL), but not in DMS79 and BcPC3 
xenograft bearing mice with no detectable serum CA19.9 
[32]. Free prostate specific antigen (PSA) targeting 
89Zr-5A10 showed a similar principle, liver uptake was 
24.6 ± 4.9%ID/g for 89Zr-5A10 in LNCaP-AR xenograft 
bearing mice in presence of 18.35 ± 2.7 ng/mL free PSA 
in serum. Liver uptake was 2.5 fold lower for both 89Zr-
5A10 in PSA-negative PC3 tumor bearing mice and 
89Zr-IgG control in LNCaP-AR tumor bearing mice [33], 
confirming the ability of circulating antigen to direct 
antibody tracers to the liver.
 In transgenic mice developing mutant and KRAS 
mutated NSCLC, murine endogenous plasma sEGFR and 
EGFR liver expression decreased after carcinogenesis 
[33]. Lower concentrations circulating sEGFR were 
also found in humans with NSCLC, when compared to 
healthy controls [22]. However, reported clinical sEGFR 
serum concentrations vary greatly depending on detection 
method and between patients and matched control groups 
[23]. sEGFR concentrations in cancer patients ranged 
between 25.5 ± 4.5 (19.4–40.1) in NSCLC vs. 35.9 ± 5.2 
(20.6–44.2) ng/mL in controls based upon a commercial 
ELISA kit (22), to 545 ± 503 (ND-2139) in metastatic 
breast cancer vs. 546 ± 706 ng/mL (12–3461) in matched 
controls based upon an acridinium-linked immunosorbent 
assay (ALISA) assay [24]. In healthy volunteers sEGFR 
serum concentrations ranged between 0.0125 and 5 μg/mL 
based upon ALISA [23], corresponding to a 140,000-fold 
or only 5-fold molar excess of cetuximab at peak and 
through concentrations compared to sEGFR [30]. In one 
patient with ovarium cancer up to 9.1 μg/mL sEGFR was 
measured [20]. It is therefore conceivable that EGFR 
targeting tracer kinetics could be influenced in a subset of 
patients with high sEGFR levels. This might be especially 
true when patient are treatment-naïve, considering many 
immunoPET agents use microdosing. If patients received 
multiple doses of EGFR antibody prior to tracer injection, 
sEGFR could already have been depleted and the sEGFR 
effect will most likely not be seen. 
Strikingly, high liver uptake and rapid blood 
clearance was shown for 89Zr-cetuximab PET in a recent 
clinical study [17,37]. 89Zr-cetuximab liver radiation 
burden in patients was up to two-fold higher [34] compared 
to antibody-based tracers anti-CD20 89Zr-ibritumumab 
tiuxetan [35] and anti-CD44v6 89Zr-cmAb U36 [36]. Liver 
uptake of up to 40 mg was also seen for murine cetuximab 
analog 111In-mAb225 in patients, while dose escalation 
up to 300 mg increased blood availability and tumor 
uptake of 111In-mAb225. [37]. Both mouse and human 
liver tissues are known to express EGFR [38], although 
liver uptake in the present study cannot be explained by 
presence of murine EGFR in liver, as imgatuzumab is not 
cross-reactive [5]. Our findings suggest that in addition to 
hepatic EGFR expression, part of the liver accumulation 
of EGFR antibody tracers in humans might be explained 
by sEGFR-tracer complexation and subsequent liver 
sequestration. This would suggest incorporating sEGFR 
analyses in preclinical and clinical EGFR imaging studies 
to assess the influence of sEGFR on EGFR tracer kinetics.
Concluding, 89Zr-imgatuzumab accumulates in and 
visualizes EGFR-expressing tumors. High shed sEGFR 
levels in blood can reduce 89Zr-imgatuzumab blood pool 
availability and lower tumor uptake, due to redirection 
of tracer-sEGFR complex to the liver. Higher tracer 
protein dose increased 89Zr-imgatuzumab tumor uptake 
by saturating sEGFR-mediated liver uptake. Combined, 
these findings could improve interpretation of (pre)clinical 
EGFR imaging by taking sEGFR levels into account. 
Furthermore, this phenomenon could possibly also apply 
to imaging of other antigens with soluble isoforms or 
which are heavily shed.
MATERIALS AND METHODS
Cell Lines 
Human cancer cell lines with varying levels of 
EGFR expression were used. The NSCLC cell lines H441 
and A549 and the epidermoid carcinoma cell line A431 
were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA). Cells were quarantined until 
screening for microbial contamination and mycoplasm was 
performed and proven to be negative. Cells were tested 
and authenticated in April 2015 by Baseclear (Leiden, The 
Netherlands) using STR profiling. Cells were subcultured 
twice weekly, using Roswell Park Memorial Institute-1640 
(RPMI-1640, Gibco, Paisley, UK)/2 mM L-glutamine 
(Gibco) supplemented with 10% fetal calf serum (FCS, 
Bodinco, Alkmaar, The Netherlands) for H441, RPMI-
1640, with 10% FCS for A549 and high glucose Dulbecco’s 
Modified Eagle’s Medium (DMEM, Gibco) with 10% FCS 
for A431. All cell lines were cultured in a fully humidified 
atmosphere at 37°C and 5% pCO
2
. Flow cytometric 
analysis was performed on a BD Accuri™ C6 flow 
cytometer (BD Biosciences, Breda, The Netherlands) to 
assess EGFR protein expression status using imgatuzumab 
(25.3 mg/mL, Roche Glycart AG, Schlieren, Switzerland) 
as primary antibody and mouse anti-human Fc-specific 
FITC conjugated secondary antibody (clone HP-6017, 
Sigma-Aldrich, Zwijndrecht, The Netherlands).
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89Zr-imgatuzumab tracer development and 
quality control
Imgatuzumab was incubated with a 5-fold molar 
excess of TFP-N-Suc-desferal-Fe (Df, ABX GmbH, 
Hamburg, Germany) and subsequent 89Zr-labeling 
was performed as described earlier [8], using clinical 
grade 89Zr (Perkin Elmer, Groningen, The Netherlands). 
Maximal attainable specific activity was determined using 
varying amounts of 89Zr per mg antibody between 50 and 
1000 MBq/mg. Radiochemical purity (RCP) was assessed 
by trichloroacetic acid (TCA) precipitation test [39]. Df-
imgatuzumab conjugates were checked for aggregation 
and fragmentation by size exclusion high performance 
liquid chromatography (SE-HPLC). The Waters SE-HPLC 
system was equipped with a dual wavelength absorbance 
detector, in-line radioactivity detector and TSK-GEL 
G3000SWXL column (JSB, Eindhoven, The Netherlands). 









; pH = 7.4) was 
used as mobile phase. Stability of 89Zr-imgatuzumab was 
tested for 2 weeks in 0.9% NaCl at 4°C, human serum at 
37°C and 0.5 M HEPES pH 7.2 buffer at 37°C. 
Immunoreactive fraction of Df-imgatuzumab 
conjugates was assessed by competition assay. In 
short, NUNC BreakApart 96-well plates were coated 
overnight at 4°C with 100 μL 100 ng/mL EGFR ECD 
(Roche Glycart AG) in 0.1 M Na
2
CO3 buffer pH 9.6. 
89Zr-imgatuzumab was diluted to 4000 ng/mL in assay 
diluent which consisted out of PBS, 0.5% bovine serum 
albumin Fraction V and 0.05% Tween 20. Plates were 
washed with washing buffer (PBS with 0.05% Tween 20) 
and blocked by 200 μL assay diluent for 1 h at room 
temperature (RT) and washed again. 0.004 to 156.25-fold 
molar excess unmodified imgatuzumab was pre-mixed 
1:1 with diluted 89Zr-imgatuzumab solution and 100 μL 
of the mixtures were incubated in wells for 1 hour at 
RT. After washing, wells were broken apart and counted 
using a calibrated well-type LKB-1282-Compu-gamma 
system (LKB WALLAC). Counts were plotted against 
concentration competing unmodified imgatuzumab and 
the half maximal inhibitory concentration (IC50) was 
calculated using Graphpad 5.0 (GraphPad Software, Inc., 
La Jolla, CA, USA). The IC50-value was divided by 
the final tracer concentration (2000 ng/mL) to yield the 
immunoreactive fraction. 
Indium-111 labeling IgG control 
Human IgG (Nanogam®, Sanquin, Amsterdam, 
The Netherlands) was used as aspecific control. IgG was 
conjugated with p-SCN-Bn-DTPA (Macrocyclics, Dallas, 
TX, USA) as described earlier [40]. Radiolabeling was 
performed using indium-111 (111In) chloride (Mallinckrodt, 
Prague, Czech Republic).
Radiochemical purity of 111In-IgG labeling was 
checked by instant thin layer chromatography (ITLC) 
using 0.1 M citrate buffer pH 6.0 as eluent. 
Animal studies
Male nude mice (BALB/cOlaHsd-Foxn1nu, Harlan, 
Boxmeer, The Netherlands) were inoculated with A431, 
H441 (both 5*106 cells in 200 µL PBS) or A549 (3*106 
in 300 µL 1:1 PBS and high growth factor Matrigel (BD 
Biosciences, Breda, The Netherlands) subcutaneously 
(sc). Xenografts were allowed to grow to at least 
100–200 mm3. For microPET imaging, A431, A549 and 
H441 xenograft-bearing mice (n = 3–6 per group) were 
injected intravenously (iv) via the penile vein with ~10, 25 
and 160 μg 89Zr-imgatuzumab (effective injected protein 
doses were 9.6 ± 0.08, 23.8 ± 0.11 and 151.2 ± 1.1 μg, 
labeled with 4.60 ± 0.06, 3.99 ± 0.13 and 5.64 ± 0.11 MBq 
89Zr respectively for the 10, 25 and 160 μg dose groups). 
MicroPET scans were made 1, 3 and 6 days post injection 
(pi) using a Focus 220 PET scanner (CTI Siemens), 
followed by ex vivo biodistribution analysis after the 
final scan. Some A431 bearing mice received ~10, 25 
or 100 μg 89Zr-imgatuzumab (effective injected protein 
doses were 9.5 ± 0.05, 23.3 ± 0.26 and 86.0 ± 4.0, labeled 
with 1.11 ± 0.03, 0.99 ± 0.06 and 0.91 ± 0.09 MBq 89Zr 
respectively for the 10, 25 and 100 μg dose groups) only 
for ex vivo biodistribution analysis 6 days pi. Ex vivo 
results of biodistribution-only A431 tumor bearing mice 
were pooled with mice used for the microPET imaging 
study, A431 tumor bearing group size was therefore 6 to 
12 animals. All mice received an equal amount of 111In-
IgG control (1 MBq) as aspecific control. For all tracer 
injections 10 μg 89Zr-imgatuzumab and an equal amount of 
111In-IgG was used, with cold imgatuzumab and IgG added 
to reach the total stated protein doses. 
Scans were reconstructed and in vivo quantification 
was performed using AMIDE (v1.0.4, Stanford University, 
Stanford, CA, USA) [41]. MicroPET data are presented 
as mean standardized uptake value (SUVmean). Region of 
interests (ROI) were drawn for tumor based upon ex vivo 
weight, assuming 1 g/ml tissue density. For blood pool 
measurements, a fixed-sized sphere was drawn in the 
center of the heart, for liver and spleen a fixed-sized 
ellipsoid ROI was drawn in representative parts of the 
organs. After the final scan, mice were sacrificed and 
organs of interest collected for biodistribution studies. 
Organs and standards of the injected tracer were counted 
in a calibrated well type LKB-1282-Compu-gamma 
system (LKB WALLAC) and weighed. After decay 
correction, ex vivo tissue activity was expressed as the 
percentage of injected dose per gram tissue (%ID/g). 
Xenograft tumors were partly formalin-fixed and paraffin 
embedded for immunohistochemistry (IHC) and partly 
frozen for subsequent sEGFR ELISA analysis. Plasma of 
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xenograft and non-xenograft bearing (control) mice was 
used for sEGFR ELISA analysis, based upon shed c-MET 
analysis by Jagoda et al. [31]. Plasma was obtained by 
heart puncture and subsequent centrifugation of blood in 
lithium heparin blood collection tubes (BD Vacutainer, 
Plymouth, UK). All animal experiments were approved 
by the Institutional Animal Care and Use Committee of 
the University of Groningen.
sEGFR ELISA analysis
Near-confluent A431, A549 and H441 cell 
cultures were washed with PBS and incubated for 72 h 
in fetal calf serum free growth media, as well as serum-
containing growth media, as described earlier [26], after 
which supernates were removed and centrifuged to 
remove cell debris. Cells of confluent cell cultures were 
washed with PBS and harvested using trypsin. Lysates 
of cells, xenograft tumors and liver tissue of A431, 
A549 and H441 xenograft bearing mice were obtained 
by mechanical disruption in M-PER Mammalian Protein 
Extraction Reagent (Thermo Scientific, Bleiswijk, The 
Netherlands) supplemented with EDTA-free protease/
phosphatase inhibitor cocktail (Thermo Scientific). 
Protein concentrations of cell, tumor and liver lysates were 
determined by Bradford assay [42]. sEGFR was detected 
using a human extracellular domain EGFR ELISA 
(SEK10001, Sino Biological, Beijing, China), according 
to manufacturer’s instructions. 
Immunohistochemistry 
Formalin fixed, paraffin-embedded tissue slices 
were stained for EGFR with a rabbit mAb (clone D38B1 
XP®, Cell Signaling Technology, Leiden, The Netherlands) 
and for microvessel density using a rat anti-murine CD31 
mAb (clone SZ31, Dianova GmbH, Hamburg, Germany). 
Hematoxylin & eosin (H&E) staining was performed 
regularly to assess tissue viability and morphology. 
Digital scans of slides were acquired by a NanoZoomer 
2.0-HT multi slide scanner (Hamamatsu) and analyzed 
with NanoZoomer Digital Pathology viewer software. 
A 0–300 EGFR staining histo-score was assessed as 
follows no staining 0+, weak cytoplasmic staining 1+, 
strong cytoplasmic staining 2+ and strong membrane and 
cytoplasmic staining 3+, with H-score calculated using 
the formula 1 × (% of 1 + cells) + 2 × (% of 2 + cells) + 
3 × (% of 3 + cells). Microvessel density was scored in 
3 areas, defined as hot spot areas with the maximum 
number of microvessels as described earlier [39] .
Statistical analysis
Data are presented as mean ± SEM. Statistical 
analyses were performed using the Mann-Whitney test 
(Graphpad 5.0) or One-way ANOVA with a Bonferroni 
post test for multiple comparisons. P-values ≤ 0.05 were 
considered significant.
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